Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials

Abstract

Key Points Question What proportion of multiple myeloma randomized clinical trials report postprotocol therapies, and when reported, how do these therapies compare with existing standard of care? Findings In this systematic review of 103 randomized clinical trials including 47 251 patients, only 43.7% of the trials reported postprotocol therapies. When described, the proportion of patients receiving postprotocol therapies was low, and often not at par with standard of care therapy. Meaning These findings suggest that reporting of postprotocol therapies is poor in multiple myeloma trials, necessitating reporting guidelines on postprotocol therapies for ongoing and future trials.